Evidence map›Paper›PMID 38256942›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network.

Miao Huang, Long Wang, Qianhui Zhang, Ling Zhou, Rui Liao, Anguo Wu, Xinle Wang, Jiesi Luo, Feihong Huang, Wenjun Zou and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Frontiers in immunology · 2025
    Review
  9. Review
  10. MAIT Cells in the Bone Marrow of Patients with Aplastic Anemia.International journal of molecular sciences · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Miao HuangState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Long WangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Qianhui ZhangState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Ling ZhouDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Rui LiaoDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Anguo WuDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0003-4688-6081
Xinle WangDepartment of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
Jiesi LuoDepartment of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-1199-7024
Feihong HuangDepartment of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Wenjun ZouState Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jianming WuDepartment of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-6136-7469
Southwest Medical University · CNChengdu University of Traditional Chinese Medicine · CNMinistry of Education of the People's Republic of China · CN

Funding

National Natural Science Foundation of China 82074129, 82204666 and 82374073State Key Laboratory of Southwestern Chinese Medicine Resources SKLTCM202313 and SKLTCM2022028
6 · The paper itself

Abstract

Interleukins, a diverse family of cytokines produced by various cells, play crucial roles in immune responses, immunoregulation, and a wide range of physiological and pathological processes. In the context of megakaryopoiesis, thrombopoiesis, and platelet function, interleukins have emerged as key regulators, exerting significant influence on the development, maturation, and activity of megakaryocytes (MKs) and platelets. While the therapeutic potential of interleukins in platelet-related diseases has been recognized for decades, their clinical application has been hindered by limitations in basic research and challenges in drug development. Recent advancements in understanding the molecular mechanisms of interleukins and their interactions with MKs and platelets, coupled with breakthroughs in cytokine engineering, have revitalized the field of interleukin-based therapeutics. These breakthroughs have paved the way for the development of more effective and specific interleukin-based therapies for the treatment of platelet disorders. This review provides a comprehensive overview of the effects of interleukins on megakaryopoiesis, thrombopoiesis, and platelet function. It highlights the potential clinical applications of interleukins in regulating megakaryopoiesis and platelet function and discusses the latest bioengineering technologies that could improve the pharmacokinetic properties of interleukins. By synthesizing the current knowledge in this field, this review aims to provide valuable insights for future research into the clinical application of interleukins in platelet-related diseases.

Indexed as

bioengineeringinterleukinsmegakaryopoiesisthrombopoiesis

Identifiers

PMID38256942
PMCPMC10820339
OpenAlexW4390882050

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.